WADA is very much aware of the development of new EPOs and biosimilar EPOs in an expanding market. A number of these new EPOs and biosimilar EPOs are well known and can be detected through current tests.
In addition to constantly refining the existing detection method for EPO and trying to anticipate doping trends, including by closely cooperating with pharmaceutical companies at very early stages of the development of molecules or substances, WADA is currently considering detection methods for EPO that will supplement the existing one and will maximize chances of detecting recombinant EPOs in athletes’ samples. It is important to remember that samples can be stored and later re-analysed as science advances. (The statute of limitations set forth in the World Anti-Doping Code is 8 years.)
In order to further improve detection of abnormal blood profiles, WADA is leading the development of a strategy against doping in sport called the "Athlete Passport", which is based on the longitudinal follow-up of an athlete's biological variables. The objective of this strategy, which will be added to other anti-doping strategies including "traditional" testing, is to detect abnormal variations of determined biological variables in order to better target testing and/or sanction those found with abnormal variations.